ANI Pharmaceuticals (ANIP)

[LordDarley]

It's never been a popular view on a Board mostly of cheerleaders, but Acthar is the name brand, and if its pricing is brought in line would still be a first choice for people already getting treated by it. Will the government stampede to it. Sure, if they want to price it at a ridiculously low price. Just review the new, sub-cost, pricing for Acthar arranged in the settlement of its Medicaid litigation.

Bottom line: the success of Corti will depend on how good MNK is at selling Acthar, and its realtively new subscription model pricing. MNK management is very smart, inherited a pile of problems, screwed shareholders, and has a big ownership stake. ANIP will have to be very good (or very low priced) to compete successfully for the "transformation." It's possible, but not a slam dunk.

As for Libigel, what can I say about this chimera, except to call it a brilliant bit of speculation by posters I like, but it is not in the ANIP future. We may be seeing the future now, an overpriced acquistion, a pile of debt, and no sales. When you miss make-believe non-GAAP numbers this badly, there is no bright horizon. Big loss (again.)